Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo

被引:411
作者
McCarty, DM
Fu, H
Monahan, PE
Toulson, CE
Naik, P
Samulski, RJ
机构
[1] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
[5] Johns Hopkins Univ, Dept Orthoped Surg, Baltimore, MD USA
关键词
AAV; double-strand; transduction; terminal repeat;
D O I
10.1038/sj.gt.3302134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An important limitation of recombinant adeno-associated virus (rAAV) vector efficiency is the requirement of host-cell-mediated synthesis of double-stranded DNA from the single-stranded genome. We have bypassed this step in a specialized self-complementary rAAV (scAAV) vector, by utilizing the tendency of AAV to package DNA dimers when the replicating genome is half the length of the wild type (wt). To produce these vectors efficiently, we have deleted the terminal resolution site (trs) from one rAAV TR, preventing the initiation of replication at the mutated end. These constructs generate single-stranded, inverted repeat genomes, with a wt TR at each end, and a mutated TR in the middle. After uncoating, the viral DNA folds through intramolecular base pairing within the mutant TR, which then proceeds through the genome to form a double-stranded molecule. We have used the scAAV to investigate barriers to rAAV transduction in the mouse liver, muscle and brain. In each tissue, scAAV was characterized by faster onset of gene expression and higher transduction efficiency. This study confirms earlier predictions that complementary-strand DNA synthesis is the primary barrier to rAAV-2 transduction. The scAAV is unaffected by this barrier, and provides an extremely efficient vector for gene transfer into many types of cells in vivo.
引用
收藏
页码:2112 / 2118
页数:7
相关论文
共 22 条
[1]   SINGLE-STRANDED DNA-PROTEIN INTERACTIONS IN CANINE PARVOVIRUS [J].
CHAPMAN, MS ;
ROSSMANN, MG .
STRUCTURE, 1995, 3 (02) :151-162
[2]  
Chen H, 1999, J NEUROSCI RES, V55, P504, DOI 10.1002/(SICI)1097-4547(19990215)55:4<504::AID-JNR10>3.0.CO
[3]  
2-0
[4]   Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus [J].
Chen, H ;
McCarty, DM ;
Bruce, AT ;
Suzuki, K ;
Suzuki, K .
GENE THERAPY, 1998, 5 (01) :50-58
[5]   Quantitative analysis of the packaging capacity of recombinant adeno-associated virus [J].
Dong, JY ;
Fan, PD ;
Frizzell, RA .
HUMAN GENE THERAPY, 1996, 7 (17) :2101-2112
[6]   Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors [J].
Ferrari, FK ;
Samulski, T ;
Shenk, T ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3227-3234
[7]   Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis [J].
Fisher, KJ ;
Gao, GP ;
Weitzman, MD ;
DeMatteo, R ;
Burda, JF ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1996, 70 (01) :520-532
[8]  
Franklin K B J, 2008, MOUSE BRAIN STEREOTA
[9]   Neurological correction of lysosomal storage in a Mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery [J].
Fu, H ;
Samulski, RJ ;
McCown, TJ ;
Picornell, YJ ;
Fletcher, D ;
Muenzer, J .
MOLECULAR THERAPY, 2002, 5 (01) :42-49
[10]   Design and packaging of adeno-associated virus gene targeting vectors [J].
Hirata, RK ;
Russell, DW .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4612-4620